Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | DHODH | Q02127 | 10/20 | 0.55 |
| ▸ | CDC7 | O00311 | 3/20 | 0.55 |
| ▸ | DBF4 | Q9UBU7 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.51 |
| ▸ | PLAT | P00750 | 1/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16597776 | 0.92 | BTK (0.59) | ALDH1A1HSD17B10HPGDDHODHCDC7 | |
| SCHEMBL17766765 | 0.85 | ALDH1A1 (0.57) | ALDH1A1HSD17B10HPGDDHODHCDC7 | |
| SCHEMBL975828 | 0.84 | ALDH1A1 (0.56) | ALDH1A1HSD17B10HPGDDHODHCDC7 | |
| SCHEMBL3658790 | 0.83 | MEN1 (0.52) | ALDH1A1CDC7DBF4MEN1KMT2A | |
| SCHEMBL16597585 | 0.82 | BTK (0.72) | ALDH1A1HSD17B10HPGDDHODHCDC7 | |
| SCHEMBL17775919 | 0.81 | ALDH1A1 (0.53) | ALDH1A1HSD17B10HPGDDHODHCDC7 | |
| SCHEMBL18017496 | 0.81 | BTK (0.70) | ALDH1A1HSD17B10HPGDDHODHCDC7 | |
| SCHEMBL16391928 | 0.80 | ALDH1A1 (0.51) | ALDH1A1HSD17B10HPGDDHODHCDC7 | |
| SCHEMBL18017539 | 0.77 | BTK (0.65) | MEN1KMT2A | |
| SCHEMBL7445418 | 0.77 | ALDH1A1 (0.42) | ALDH1A1HSD17B10HPGDDHODHMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771357-B2 | ALXR agonist compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-09-26 | — | — | US | disclosed |
| US-9771357-B2 | ALXR agonist compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-09-26 | — | — | US | disclosed |
| US-9771357-B2 | ALXR agonist compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-09-26 | — | — | US | disclosed |
| US-20160145249-A1 | ALXR AGONIST COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-26 | — | — | US | disclosed |
| US-20160145249-A1 | ALXR AGONIST COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-26 | — | — | US | disclosed |
| US-20160145249-A1 | ALXR AGONIST COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-05-26 | — | — | US | disclosed |
| WO-2015005305-A1 | ALXR AGONIST COMPOUND | 小野薬品工業株式会社 (JP) | 2015-01-15 | — | — | WO | disclosed |
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-8673911-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2014-03-18 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2014-02-13 | — | — | US | disclosed |
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2011-01-27 | — | — | US | disclosed |
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021771-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | ALDH1A1 699/4885HSD17B10 527/4885HPGD 326/4885 |
| US-20140045850-A1 | INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC11, HDAC3 | ALDH1A1 699/4885HSD17B10 527/4885HPGD 326/4885 |
| US-20160145249-A1 | ALXR AGONIST COMPOUND | MRGPRX2, MRGPRX1, MRGPRX4 | ALDH1A1 1112/4885HSD17B10 665/4885HPGD 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.